(Q33495790)

English

Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

phosphorylation

0 references

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

author name string

Zhe Zhang

1

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Xiaoyun Zhou

2

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Hujia Shen

3

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Dexing Wang

4

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Yanhong Wang

5

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

language of work or name

0 references

publication date

24 August 2009

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

41

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738687

21 June 2018

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738687

21 June 2018

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738687

21 June 2018

Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738687

21 June 2018

Management of hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738687

21 June 2018

Global cancer statistics, 2002

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738687

21 June 2018

Angiogenesis and hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738687

21 June 2018

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738687

21 June 2018

Stepwise metastatic human hepatocellular carcinoma cell model system with multiple metastatic potentials established through consecutive in vivo selection and studies on metastatic characteristics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738687

21 June 2018

Hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738687

21 June 2018

Role of MAP kinase in tumor progression and invasion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738687

21 June 2018

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738687

21 June 2018

Targeting RAS signalling pathways in cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738687

21 June 2018

Transcriptional activation of the thyroglobulin promoter directing suicide gene expression by thyroid transcription factor-1 in thyroid cancer cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738687

21 June 2018

New human hepatocellular carcinoma (HCC) cell line with highly metastatic potential (MHCC97) and its expressions of the factors associated with metastasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2738687

21 June 2018

Potentiation of the antitumor effects of both selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatic cancer cells by inhibition of the MEK/ERK pathway.

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-7-41

21 January 2018

Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-7-41

21 January 2018

High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19698189

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19698189

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1741-7015-7-41

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33495790&oldid=2195416386"